BCL6 IHC (protein expression)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-BCL6-IHC |
|---|---|
| Type | Biomarker |
| Aliases | B-cell lymphoma 6 proteinBCL-6 IHCBCL6 immunohistochemistryBCL6 protein |
| Status | reviewed 2026-05-05 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-B-CELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Mutation details | {"gene_id_ncbi": 604, "gene_symbol": "BCL6", "note": "BCL6 is a transcriptional repressor essential for germinal center (GC) B-cell development. BCL6 IHC detects nuclear protein expression (not rearrangement). Positive = nuclear staining. Threshold: >30% nuclear positivity typically used as cut-off for GC-origin classification (Hans algorithm). Note: BIO-BCL6-REARRANGEMENT is a distinct biomarker (chromosomal translocation detected by FISH) — different from BCL6 protein expression by IHC.\n"} |
| Measurement | MethodIHC on FFPE biopsy. Anti-BCL6 antibody (clone PG-B6p). Nuclear staining scored as % positive tumor cells. Hans algorithm threshold: >30% nuclei positive = BCL6+. Automated scoring on digital pathology platforms increasingly used. |
| Related biomarkers | BIO-CD10-IHC BIO-MUM1-IHC BIO-DLBCL-COO-HANS BIO-BCL6-REARRANGEMENT BIO-MYC-REARRANGEMENT |
Notes
BCL6 IHC is a core component of the Hans algorithm for DLBCL cell-of-origin classification. While gene expression profiling (GEP, Lymph2Cx assay) is the reference standard for GCB/ABC classification, Hans IHC is widely used in resource-limited settings (concordance with GEP ~80%). BCL6 protein expression is distinct from BCL6 chromosomal rearrangement (t(3;v) translocations detected by FISH) — both exist independently. BCL6 rearrangement occurs in ~25-35% of DLBCL and may be present in either GCB or non-GCB subtypes.
Used By
Biomarker
BIO-CD10-IHC- CD10 IHC (CALLA, neprilysin)BIO-MUM1-IHC- MUM1/IRF4 IHC (Multiple Myeloma oncogene 1)